Peer Review reports
From: Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
| Original Submission | ||
|---|---|---|
| 14 Mar 2020 | Submitted | Original manuscript |
| 30 Mar 2020 | Author responded | Author comments - Martin Valis |
| 10 Apr 2020 | Reviewed | Reviewer Report |
| 17 Apr 2020 | Reviewed | Reviewer Report - Jessica Frau |
| 3 May 2020 | Author responded | Author comments - Martin Valis |
| Resubmission - Version 2 | ||
| 30 Mar 2020 | Submitted | Manuscript version 2 |
| 6 May 2020 | Reviewed | Reviewer Report |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| Publishing | ||
| 14 May 2020 | Editorially accepted | |
| 21 May 2020 | Article published | 10.1186/s12883-020-01789-y |
You can find further information about peer review here.